Jae-Heon Jeong

Learn More
BACKGROUND Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an independent prognostic marker in cancer. METHODS The significance of TGase 2 expression as an invasive/migratory factor was addressed by in(More)
BACKGROUND The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and(More)
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-κB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-κB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients(More)
Plasma cell myeloma (PCM) is a malignant hematologic disease characterized by the proliferation of neoplastic plasma cells, producing excessive amounts of monoclonal immunoglobulin (Ig) or light chain (LC) [1, 2]. Although plasma cells are widely distributed throughout the body, PCM is found most often within the bone and bone marrow (BM), while the(More)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. We read with interest the article " EML4-ALK Fusion Gene in Korean Non-Small Cell Lung Cancer " in a recent issue of the Journal of Korean Medical Science by Jin et al. (1). In this study, EML4-ALK fusion gene was(More)
  • 1